ECOG-InPact
International Penile Advanced Cancer Trial (ILND; or Neoadjuvant chemo + ILND; or Synchronous Chemo [neo adj. or adjuvant]; or prophylactic pelvic LND)
Inclusion Criteria:
-
Histologically-proven squamous cell carcinoma of the penis
-
Stage: and T, N1-3, MO
-
Measurable disease as determined by RECIST 1.1
Exclusion Criteria:
-
Pure verrucous carcinoma/non-squamous malignancy of the penis; squamous carcinoma of the urethra
-
Stage M1
-
Previous chemotherapy/chemoradiotherapy outside of the InPACT trial
Principal Investigator:
Co-Investigators & Collaborators:
Department of Urology: Kenneth Ogan, MD, Department of Hematology and Medical Oncology: Mehmet Bilen, MD, Bradley Carthon, MD, PhD, Omer Kucuk, MD, David Lawson, MD, Department of Radiation Oncology: Joseph Shelton, MD, Ashesh Jani, MD